117 related articles for article (PubMed ID: 7648289)
1. Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity.
Neyts J; De Clercq E
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):8-12. PubMed ID: 7648289
[TBL] [Abstract][Full Text] [Related]
2. 3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection.
Kokuba H; Aurelian L; Neurath AR
Antivir Chem Chemother; 1998 Jul; 9(4):353-7. PubMed ID: 9875414
[TBL] [Abstract][Full Text] [Related]
3. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses.
Piret J; Lamontagne J; Bestman-Smith J; Roy S; Gourde P; Désormeaux A; Omar RF; Juhász J; Bergeron MG
J Clin Microbiol; 2000 Jan; 38(1):110-9. PubMed ID: 10618073
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice.
Carlucci MJ; Scolaro LA; Noseda MD; Cerezo AS; Damonte EB
Antiviral Res; 2004 Nov; 64(2):137-41. PubMed ID: 15498610
[TBL] [Abstract][Full Text] [Related]
6. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression.
Guzman EM; Cheshenko N; Shende V; Keller MJ; Goyette N; Juteau JM; Boivin G; Vaillant A; Herold BC
Antivir Ther; 2007; 12(8):1147-56. PubMed ID: 18240855
[TBL] [Abstract][Full Text] [Related]
7. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: impact on the search for vaginal microbicides.
Neyts J; Kristmundsdóttir T; De Clercq E; Thormar H
J Med Virol; 2000 May; 61(1):107-10. PubMed ID: 10745241
[TBL] [Abstract][Full Text] [Related]
8. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
9. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
[TBL] [Abstract][Full Text] [Related]
10. An improved system for the evaluation of antiviral compounds against herpes simplex virus type 2.
Yin S; Li Y; Xia H; Zhao J; Zhang Z; Tang S; Kou Z; Chen J; Yu J; Fan Z; Li T
J Virol Methods; 2013 May; 189(2):317-20. PubMed ID: 23454799
[TBL] [Abstract][Full Text] [Related]
11. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.
Palliser D; Chowdhury D; Wang QY; Lee SJ; Bronson RT; Knipe DM; Lieberman J
Nature; 2006 Jan; 439(7072):89-94. PubMed ID: 16306938
[TBL] [Abstract][Full Text] [Related]
12. Anti-herpes simplex virus activity of sulfated galactans from the red seaweeds Gymnogongrus griffithsiae and Cryptonemia crenulata.
Talarico LB; Zibetti RG; Faria PC; Scolaro LA; Duarte ME; Noseda MD; Pujol CA; Damonte EB
Int J Biol Macromol; 2004 Apr; 34(1-2):63-71. PubMed ID: 15178011
[TBL] [Abstract][Full Text] [Related]
13. Seminal plasma reduces the effectiveness of topical polyanionic microbicides.
Patel S; Hazrati E; Cheshenko N; Galen B; Yang H; Guzman E; Wang R; Herold BC; Keller MJ
J Infect Dis; 2007 Nov; 196(9):1394-402. PubMed ID: 17922405
[TBL] [Abstract][Full Text] [Related]
14. Topical microbicides for the prevention of genital herpes infection.
Keller MJ; Tuyama A; Carlucci MJ; Herold BC
J Antimicrob Chemother; 2005 Apr; 55(4):420-3. PubMed ID: 15743896
[TBL] [Abstract][Full Text] [Related]
15. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
16. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
17. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
18. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
Celum CL; Robinson NJ; Cohen MS
J Infect Dis; 2005 Feb; 191 Suppl 1():S107-14. PubMed ID: 15627220
[TBL] [Abstract][Full Text] [Related]
19. Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides.
Rusnati M; Vicenzi E; Donalisio M; Oreste P; Landolfo S; Lembo D
Pharmacol Ther; 2009 Sep; 123(3):310-22. PubMed ID: 19447134
[TBL] [Abstract][Full Text] [Related]
20. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons.
Strick LB; Wald A; Celum C
Clin Infect Dis; 2006 Aug; 43(3):347-56. PubMed ID: 16804851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
